Kolon Life Science announced on March 11 that its osteoarthritis cell and gene therapy “TG-C,” developed by Kolon TissueGene, has been granted a patent in Japan. The patent is for a “pharmaceutical composition for the prevention or treatment of osteoarthritis” related to TG-C. TG-C is a medication t
The authors are analysts of Shinhan Investment Corp. They can be reached at bh.lee@shinhan.com and jiwoo100@shinhan.com, respectively. -- Ed. Domestic market leader in artificial jointsCorentec designs, manufactures and markets orthopedic artificial joint systems. With its locally-produced artificia
Despite the die-hard COVID-19 pandemic, Dongkook Pharmaceutical is enjoying brisk exports of its products.In 2020, the company exported intravenous anesthetic "Pofol Injection" to the Netherlands, Luxembourg, Singapore, and Japan as an emergency supply. It will export the product to Colombia this mo
Google’s in-app payment and 30 percent fee were covered at the parliamentary inspection of the Ministry of Science and ICT that took place on Oct. 7. National Assembly members urged the passage of a Telecommunications Business Act amendment against in-app payment.Democratic Party of Korea lawmaker H
Kia Motors Corp. is stepping up its efforts to penetrate the global purpose-built vehicle (PBV) market, which is expected to account for 25 percent of global demand for automobiles in 2030.Kia Motors announced on June 16 that president Song Ho-sung, who was appointed as CEO at a board meeting on Jun
The Korea Institute of Medical Microrobotics (KIMIRo) announced on Feb. 16 that it has succeeded for the first time in the world in knee cartilage regeneration by means of a stem cell held by a microrobot. Details of the research were published in the Science Robotics journal on Jan. 22 after verifi
Kolon Life Science Inc. has voluntarily suspended sales of Invossa-K Inj. (gene therapy), a degenerative arthritis treatment, as a cell line different from the one permitted by the Ministry of Food and Drug Safety (MFDS) has been discovered.The MFDS requested that Kolon Life Science discontinue manu
Most of foreign companies listed on the domestic stock market over the past three years showed poor performance. All but one fell below their initial public offering (IPO) prices. They suffered a drop of 38 percent from the IPO prices on average.The number of foreign firms listed on the domestic sto
South Korean healthcare wearables maker Exosystems, a member company of the K-ICT Born2Global Centre, will demonstrate its latest AI-based technology at CES 2019 next month.The exoRehab device was created by the company to give patients a "personalized rehabilitation guidance" during their neuromusc
Kolon Life Science announced on Nov. 19 that it has signed a technology export contract with multinational pharmaceutical company Mundipharma to launch Invossa-K, a cell gene therapy for osteoarthritis treatment developed by its subsidiary Kolon TissueGene, in Japan.The total contract amount is 667.
MediPost's degenerative arthritis treatment “Cartistem,” which has been leading the domestic stem cell therapy market, has exceeded 10,000 treatments in cumulative sales in six years after the launch.According to the industry on Nov. 1, Cartistem achieved the milestone last month. In 2012, the y
Hyundai Motor Group is actively developing wearable industrial robots to be used at its plants, while at the same time stepping up efforts to jump into the robotic business by developing commercial robots.Hyundai Motor Group announced in September that it would apply “H-CEX,” a chair-type wearable r
Medical equipment stocks has received a big boost from the government’s announcement that it would significantly ease regulations on medical devices and reduce the time it takes for new medical devices to enter the market. The beneficiaries of the government’s belated deregulation initiative are sto
Invossa, Korea's first gene therapy drug for knee osteoarthritis developed by the Kolon Group, made a foray into China, the largest market in Asia. Kolon signed a contract to supply 230 billion won (US$207 million) worth of Invossa to Henan Province in China for five years. The deal represents o
Invossa, South Korea’s first gene therapy for knee osteoarthritis developed by the Kolon Group, has crossed the final threshold for the phase 3 clinical trial in the US.Kolon TissueGene, an affiliate of the Kolon Group, announced on July 6 that the company has got approval of its use of the clinical
Kolon Life Science Inc. will export Invossa K, the world’s first cell and gene therapy for knee osteoarthritis, to Hong Kong, Macao and Mongolia.The company announced on June 20 that it has signed a 16.9 billion won (US$15.25 million) contract with Zhongji 1 International Medical Group in Hong Kong
Lee Beom-seok, president of Kolon TissueGene Inc., is confident that the US Food and Drug Administration will give the green light to phase III clinical trials on Invossa, the world’s first knee osteoarthritis genetic therapy.“We have already secured 60 sites for the clinical trials and will add ano
Kolon Group was given the green light for exporting Invossa, the world's first cell gene-based osteoarthritis drug, to the Middle East.Lee Woong-yeol, chairman of the Kolon Group, met with Sheikh Saud Bin Saqr Al Qasimi, current emir of Ras Al Khaimah, who was visiting Korea in Kolon One & Only
The Hyundai Motor Group will introduce wearable robots to automobile production lines late this year. This will mark the first time that a wearable robot is put into an automobile production line in Korea. Wearable robots are literally robots that workers wear to work better and faster at their work
Amid local bio pharmaceutical companies’ active development of new drug technologies, the Korean bio pharmaceutical industry shows mixed results in new technology exportation. The technology export of Kolon Life Science’s degenerative arthritis drug “Invossa” worth 440 billion won (US$407.11 million